<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56830">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01654133</url>
  </required_header>
  <id_info>
    <org_study_id>12-0062</org_study_id>
    <nct_id>NCT01654133</nct_id>
  </id_info>
  <brief_title>Visceral (Kidney and Abdominal Organ) Function After Endovascular Aneurysm Repair (EVAR)</brief_title>
  <official_title>Evaluation of Visceral Function Following Endovascular Aortic Aneurysm Repair (EVAR) Using Branch Stent-Grafts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mark Farber, MD, FACS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UNC Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cook</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate visceral function, after endovascular repair of
      thoracoabdominal aneurysms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the effect of endovascular repair of  complex (Type II, III, and
      IV) thoracoabdominal aortic aneurysms on visceral function using the Zenith p-Branch
      Endovascular Stent Graft and the Zenith Physician Specified Stent Grafts.  Specifically, the
      device orientation and configuration will be evaluated with respect to renal function.
      Since detailed CT scan imaging will be performed prior to and after endovascular repair,
      critical data concerning each branched vessel length, tangential orientation from the aorta,
      angle of incidence, and diameter can be determined.  This information can then be coupled
      with hemodynamic data obtained from duplex ultrasonography as well as changes in renal
      volume, eGFR, and flow characteristics over time.  By analyzing the data in this fashion, it
      may be possible to determine changes in hemodynamics and/or physiologic conditions with
      respect to branched stent-graft design characteristics.  These data may be utilized to
      enhance current device design and improve patient outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Change from baseline in renal function over time (up to two years) after endovascular aortic aneurysm repair using the Zenith p-Branch stent graft</measure>
    <time_frame>Pre-procedure and  1,  6, 12, 18,  and 24 months post procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visceral function after endovascular repair of pararenal aneurysms using the Zenith® p-Branch™ stent graft.  Specifically, the device orientation and configuration will be evaluated with respect to renal function over time.  Critical data concerning each branched vessel from radiological studies coupled with hemodynamic data obtained from renal artery duplex, changes in renal volume, eGFR, and flow characteristics at 1, 6, 12, 18 and 24 months post procedure may make it possible to determine changes in renal function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to morbidity</measure>
    <time_frame>30 days and 1 &amp; 2 years post procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Morbidity at 30 days, 1 &amp; 2 years post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to mortality</measure>
    <time_frame>30 days and 1 &amp; 2 years post procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mortality at 30 days, 1 &amp; 2 years post procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to loss of stent graft integrity</measure>
    <time_frame>30 days and 1  &amp;  2 years post procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evidence on contrast CTA of loss of stent graft integrity at 30 days, and one and two years post procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to migration</measure>
    <time_frame>30 days and 1  &amp;  2 years post procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evidence of stent graft migration on abdominal x-rays at 30 days and 1 &amp; 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoleak</measure>
    <time_frame>30 days and 1 &amp; 2 years post procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evidence of Endoleak on contrast CTA of abdomen 30 days and 1 &amp; 2 years post procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Branch vessel Events</measure>
    <time_frame>30 days and 1  &amp;  2 years post procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evidence of branch vessel events on contrast CTA and renal duplex 30 days, and 1 &amp; 2 years post procedure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Aortic Aneurysm, Abdominal</condition>
  <arm_group>
    <arm_group_label>enodvascular repair TAAA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endovascular repair of TAAA using Zenith p-branch endovascular stent graft</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zenith p-Branch endovascular stent graft</intervention_name>
    <description>Repair of thoracoabdominal aortic aneurysms</description>
    <arm_group_label>enodvascular repair TAAA</arm_group_label>
    <other_name>Endovascular repair of thoracoabdominal aortic aneurysm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients may be included in the study if the patient has at least one of the following and
        has aortic anatomy appropriate for treatment with the Zenith® p-Branch™ Endovascular
        Graft:

          1. Pararenal or juxtarenal aortic aneurysm with an orthogonal aortic diameter

               1. Greater than or equal to 5 cm, or

               2. greater than two times the normal aortic diameter

          2. Rapid aortic enlargement (&gt; than or equal to 5mm in 1 year)

          3. Presence of a saccular aneurysm at risk for rupture based on investigators evaluation

        Exclusion Criteria:

        General Exclusion Criteria

        Patients must be excluded from the study if any of the following conditions are true:

          1. Less than 18 years of age

          2. Unwilling to comply with the follow-up schedule

          3. Inability or refusal to give informed consent

        Medical Exclusion Criteria

        Patients must be excluded from the study if any of the following conditions are true:

          1. Known sensitivities or allergies to stainless steel, nitinol, polyester, solder (tin,
             silver), polypropylene, urethane or gold

          2. History of anaphylactic reaction to contrast material that cannot be adequately
             premedicated

          3. Leaking, ruptured aneurysm associated with hypotension

          4. Uncorrectable coagulopathy

        Anatomical Exclusion Criteria

        Patients must be excluded from the study if any of the following conditions are true:

          1. Inadequate femoral/iliac access compatible with the required delivery systems;

          2. Does not have a non-aneurysmal aortic segment proximal to the aneurysm with:

               1. A length of at least 4 mm, i.e. at least 4 mm circumferential wall contact
                  around the limits of scallop

               2. A diameter measured outer wall to outer wall of no greater than 31mm and no less
                  than 21 mm;

               3. An angle less than 60 degrees relative to the centerline of the aneurysm;

               4. An angle less than 45 degrees relative to the supraceliac aorta.

          3. Does not have visceral vessel anatomy compatible with Zenith® p-Branch™,
             specifically:

               1. Renal vessel origins as measured relative to the SMA compatible with the renal
                  fenestration, i.e. Both renal vessel origins within 7.5mm of the corresponding
                  renal fenestrations;

               2. Celiac vessel origin as measured relative to the SMA compatible with the celiac
                  scallop.

          4. A proximal seal site with unsuitable thrombus/atheroma

          5. Does not have iliac artery fixation sites and anatomy consistent with:

               1. Common iliac artery fixation site diameter, measured outer wall to outer wall on
                  a sectional image (CT) &lt;8.0 mm (prior to deployment)

               2. Iliac artery diameter, measured outer wall to outer wall on a sectional image
                  (CT) &gt;21 mm at distal fixation site

               3. Iliac artery distal fixation site &lt;10 mm in length

               4. Inability to preserve at least one hypogastric artery

                  -

                  -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A Farber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill, NC   27599</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC Heart and Vascular</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 1, 2014</lastchanged_date>
  <firstreceived_date>July 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Mark Farber, MD, FACS</investigator_full_name>
    <investigator_title>Director of Aortic Disease Center,  Associate Professor Surgery &amp; Radiology</investigator_title>
  </responsible_party>
  <keyword>Aortic Aneurysm, abdominal</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
